Masimo Corporation
Masimo Announces Potential Separation of Consumer Business
Summary
Masimo Corporation disclosed an update on the potential separation of its consumer business, which involves a non-binding term sheet with a potential joint venture partner. The partner is interested in acquiring a majority of Masimo's consumer business for a purchase price between $850 million and $950 million. Discussions are ongoing, and the terms are subject to change. The transaction also involves intellectual property rights and potential strategic partners. The company is advised by Morgan Stanley and outside counsel.
Profitelligence Alerts
Get alerts for MASI
Be first to know when Masimo Corporation files with the SEC.
Filing Categories
Advertisement
About Masimo Corporation
Masimo Corporation is a global leader in noninvasive monitoring technologies, specifically focusing on developing innovative medical devices that improve patient outcomes and reduce the cost of care. The company's flagship product line includes advanced signal processing pulse oximetry devices, which are pivotal in accurately measuring oxygen levels, pulse rate, and other vital signals without the need for invasive procedures. Masimo's technology is widely adopted across various healthcare settings including hospitals, outpatient treatment centers, and alternative care sites, enhancing patient monitoring and aiding clinicians in detecting potential health issues more efficiently. Besides, Masimo’s products are recognized for their precision and reliability, demonstrating robustness even in challenging clinical environments where motion and low perfusion can affect monitoring accuracy. The corporation is committed to expanding its technological suite, covering a spectrum of health monitoring solutions that contribute to improved healthcare practices globally. Based in Irvine, California, Masimo's ongoing innovation continues to set benchmarks in the healthcare industry, influencing a wide range of sectors from emergency care to surgical and critical care monitoring.
Official SEC Documents
Advertisement